As our clinical data showed a significant association between XIAP over-expression and activated AKT and it has also been shown that XIAP and AKT are inter-linked in various cancer [12, 30], we speculated that combination of PI3-kinase inhibitor with embelin would be a suitable strategy to treat breast cancer cells. Here, AKT1 is linked to breast carcinoma.